Literature DB >> 8349438

Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.

M Moore1, J Maroun, F Robert, R Natale, J Neidhart, B Dallaire, R Sisk, J Gyves.   

Abstract

Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8349438     DOI： 10.1007/bf00873913

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

1.  Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Authors:  D A Noe; E K Rowinsky; H S Shen; B V Clarke; L B Grochow; W B McGuire; A Hantel; D B Adams; M D Abeloff; D S Ettinger
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

2.  Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.

Authors:  S F Chen; R L Ruben; D L Dexter
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

3.  DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.

Authors:  G Schwartsmann; G J Peters; E Laurensse; F C de Waal; A H Loonen; A Leyva; H M Pinedo
Journal:  Biochem Pharmacol       Date:  1988-09-01       Impact factor: 5.858

4.  A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Authors:  E Bork; S Vest; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

5.  Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

Authors:  D L Dexter; D P Hesson; R J Ardecky; G V Rao; D L Tippett; B A Dusak; K D Paull; J Plowman; B M DeLarco; V L Narayanan
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Authors:  G Schwartsmann; P Dodion; J B Vermorken; W W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; W J van der Vijgh; M B van Hennik
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).

Authors:  C L Arteaga; T D Brown; J G Kuhn; H S Shen; T J O'Rourke; K Beougher; H J Brentzel; D D Von Hoff; G R Weiss
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701
  7 in total
  10 in total

1.  The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.

Authors:  David B Sykes
Journal:  Expert Opin Ther Targets       Date:  2018-10-17       Impact factor: 6.902

2.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

3.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

4.  Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).

Authors:  Marianne Lucas-Hourani; Hélène Munier-Lehmann; Farah El Mazouni; Nicholas A Malmquist; Jane Harpon; Eloi P Coutant; Sandrine Guillou; Olivier Helynck; Anne Noel; Artur Scherf; Margaret A Phillips; Frédéric Tangy; Pierre-Olivier Vidalain; Yves L Janin
Journal:  J Med Chem       Date:  2015-06-30       Impact factor: 7.446

Review 5.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

6.  Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.

Authors:  Yajie Yu; Jane Ding; Shunqin Zhu; Ahmet Alptekin; Zheng Dong; Chunhong Yan; Yunhong Zha; Han-Fei Ding
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

7.  Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.

Authors:  Arthur Branstrom; Liangxian Cao; Bansri Furia; Christopher Trotta; Marianne Santaguida; Jason D Graci; Joseph M Colacino; Balmiki Ray; Wencheng Li; Josephine Sheedy; Anna Mollin; Shirley Yeh; Ronald Kong; Richard Sheridan; John D Baird; Kylie O'Keefe; Robert Spiegel; Elizabeth Goodwin; Suzanne Keating; Marla Weetall
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

Review 8.  Role of pH in Regulating Cancer Pyrimidine Synthesis.

Authors:  Saad Saeed Alqahtani; Tomas Koltai; Muntaser E Ibrahim; Adil H H Bashir; Sari T S Alhoufie; Samrein B M Ahmed; Daria Di Molfetta; Tiago M A Carvalho; Rosa Angela Cardone; Stephan Joel Reshkin; Abdelhameed Hifny; Mohamed E Ahmed; Khalid Omer Alfarouk
Journal:  J Xenobiot       Date:  2022-07-06

9.  Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.

Authors:  Joseph T Madak; Christine R Cuthbertson; Yoshinari Miyata; Shuzo Tamura; Elyse M Petrunak; Jeanne A Stuckey; Yanyan Han; Miao He; Duxin Sun; Hollis D Showalter; Nouri Neamati
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

Review 10.  Small molecule activators of the p53 response.

Authors:  Marcus J G W Ladds; Sonia Laín
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.